It's a rare stock that can actualy see it's 52 week high in the distance and have a good chance of getting there. Harmony is one such stock. rev of $364 mil <-- they make money. This can often and ironically be a negative thing in Biotech investing... some day I'll get into it. But Biotechs are birthed with much fanfare they stow away cash from investors along the way as they dribble out Press Releases about long shot ideas... but once the product is out and the cash is coming in rather than cheer to the heavens, Biotech investors often start looking for the next birth. EBITDA 131.M Where this idea gets interesting: Float 31 mil aprox Shares Short (Sep 30, 2022) 6.06M Short Ratio (Sep 30, 2022) 11.76 Short % of Float (Sep 30, 2022)---> 21.24%That's as of Sept maybe Van can get a fresher number. Harmony Biosciences Holdings, Inc. (HRMY) NasdaqGM - NasdaqGM Real Time Price. 47.63+0.99(+2.12%) At close: October 13 04:00PM EDT 50.50+2.87(+6.03%)<--------------- Pre-Market:08:00AM EDT Jefferies upgrades 'undervalued' Harmony Biosciences to Buy 07:59 HRMY As previously reported, Jefferies analyst Chris Howerton upgraded Harmony Biosciences to Buy from Hold with a price target of $61, up from $57. With an estimated 34% annualized revenue growth rate, which Howerton calls out as "the highest among biotech stocks with positive net income," the shares are "undervalued." He sees "no slowing down" of Wakix's linear uptake on an annualized basis and thinks it deserves a higher premium for its growth, Howerton said, adding that he sees Harmony "quickly filling the piggy bank and looking for somewhere to put it" and that it is not hard for him to imagine an accretive acquisition at current valuations. Show Related Items >>
U.S. Bancorp sees Q4 revenue up roughly 2% vs. Q3, consensus $6.59B 06:56 USB Sees Q4 core expenses up 2% vs. Q3. Comments taken from Q3 earnings conference call presentation slides.
STOCK OF THE DAY- Axsome This was up 11% yest! Because a competitor tripped up- Always a good set up. Relmada Tanks After 'Paradoxical Results' Undermine Depression Drug; Axsome Surges Axsome Therapeutics, Inc. (AXSM) NasdaqGM - NasdaqGM Real Time Price. 46.21+4.78(+11.54%) At close: October 13 04:00PM EDT 47.20+0.99(+2.14%)<---------------- Pre-Market:09:06AM EDT Relmada failure 'direct net positive' for Axsome, says Mizuho 06:48 AXSM, RLMD Shares of Axsome Therapeutics (AXSM) closed up 12% yesterday following the announcement of negative Phase 3 data for REL-1017, a novel NMDA receptor antagonist being developed by Relmada Therapeutics (RLMD) for the treatment of major depressive disorder, Mizuho analyst Graig Suvannavejh tells investors in a research note. The negative outcome for Relmada is a "direct net positive" for Axsome, says the analyst. He notes that while Axsome has yet to launch Auvelity, REL-1017 has been viewed as a meaningful near-term competitor in an "already crowded" major depressive disorder landscape. He believes the he negative Phase 3 data for REL-1017 comes as a "welcome relief with respect to Auvelity's near-term prospects." Suvannavejh keeps a Buy rating on Axsome with a $76 price target.
Cramer nailed the bottom yesterday too btw. Told his club to get long for the squeeze. It was an amazing call Stoney. A 5% rally on the Naz. It even impressed the savant.
I thought Cramer was a lot better this morning. He set me off yesterday. Now I feel guilty. I know he reads all of this stuff-- I've talked with his assistant about this through emails. I've got to control myself or he will never have me on air. I've been a thorn in his bonnet for maybe 25 years! Since the very start of The Street.com... Jimmy was very good on the Albertson's merger today. The other day when he talked about rich people in the third person as if he wasn't one... please...
Boeing. Van thoughts? Rumor of an airline making a large very large wide body order. Cramer likes Delta.